Biocryst Pharmaceuticals (BCRX) Net Income towards Common Stockholders (2010 - 2026)

Biocryst Pharmaceuticals (BCRX) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$721.8 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 2255762.5% year-over-year to -$721.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$458.0 million (down 756.52% YoY) and the FY2025 annual result came in at $263.9 million, up 396.87% from the prior year.
• Net Income towards Common Stockholders fell to -$721.8 million in Q1 2026, from $245.8 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $245.8 million in Q4 2025 to a low of -$721.8 million in Q1 2026.
• A 5-year average of -$60.0 million and a median of -$36.1 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2025 — Net Income towards Common Stockholders surged 1017.5% — and 2026, when it tumbled 2255762.5%.
• Tracing BCRX's Net Income towards Common Stockholders over 5 years: stood at -$71.5 million in 2022, then increased by 13.71% to -$61.7 million in 2023, then surged by 56.59% to -$26.8 million in 2024, then surged by 1017.5% to $245.8 million in 2025, then tumbled by 393.6% to -$721.8 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$721.8 million (Q1 2026), $245.8 million (Q4 2025), and $12.9 million (Q3 2025), per Business Quant data.